PI
EGRX

PEAK6 Investments’s Eagle Pharmaceuticals, Inc. EGRX Stock Holding History

PEAK6 Investments’s Portfolio EGRX Stock Details EGRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2019
Q3 		– Sell
-365
Closed -$20K – 4404
2019
Q2 		$20K Sell
365
-3,311
-90% -$173K ﹤0.01% 3432
2019
Q1 		$186K Sell
3,676
-4,425
-55% -$197K ﹤0.01% 2966
2018
Q4 		$326K Buy
+8,101
New +$417K ﹤0.01% 2672

Other funds holding EGRX

Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
PWAM
Park West Asset Management San Francisco, California $1.18B AUM 47.25% 1-Year Est. Return
HEC
Hudson Executive Capital New York $151M AUM 60.14% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
LSV Asset Management
LSV Asset Management Chicago, Illinois $46.4B AUM 27.74% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return
Norges Bank
Norges Bank Oslo, Norway $935B AUM

PEAK6 Investments's EGRX Position: Q3 2019 in Review

PEAK6 Investments sold out of Eagle Pharmaceuticals, Inc. (EGRX) in Q3 2019, closing a stake of 365 shares — an estimated $20K sold.

PEAK6 Investments first reported a position in EGRX in Q4 2018 and held it in 3 quarters. The position peaked at $326K in Q4 2018. 183 funds tracked by Wall St. Rank hold EGRX as of Q3 2019.

  • PEAK6 Investments reported no remaining Eagle Pharmaceuticals, Inc. position as of Q3 2019 after selling out during the quarter.
  • PEAK6 Investments sold 365 Eagle Pharmaceuticals, Inc. shares in Q3 2019, an estimated $20K.
  • PEAK6 Investments first reported a position in Eagle Pharmaceuticals, Inc. in Q4 2018 and held it in 3 quarters.
  • PEAK6 Investments's Eagle Pharmaceuticals, Inc. position peaked at $326K in Q4 2018.
  • 183 funds tracked by Wall St. Rank held Eagle Pharmaceuticals, Inc. as of Q3 2019.

Based on PEAK6 Investments's 13F filing for Q3 2019, filed 8 Nov 2019.